CM-101 is under clinical development by Chemomab Therapeutics and currently in Phase II for Liver Fibrosis. According to GlobalData, Phase II drugs for Liver Fibrosis does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the CM-101 LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CM-101 overview
CM-101 is under development for the treatment of liver fibrosis in patients with non-alcoholic steatohepatitis, non-alcoholic fatty liver disease, idiopathic pulmonary fibrosis, primary sclerosing cholangitis COVID-19 pneumonia, and severe acute respiratory syndrome coronavirus 2 (SARS-COV-2). The drug candidate is a humanized monoclonal antibody devoid of T cell epitopes. It is developed based on composite human antibody technology. The drug candidate targets CCL24. It is administered through intravenous and subcutaneous route. It was laso under development for systemic sclerosis.
Chemomab Therapeutics overview
Chemomab Therapeutics (Chemomab), formerly Anchiano Therapeutics Ltd, is a clinical stage biopharmaceutical company that focuses on the discovery, development, and commercialization of therapies for the unmet needs of fibrotic and inflammatory diseases. Its pipeline drug candidate is CM-101 focused on CCL24 that is advanced in PSC and SSc orphan drug indications. The company operates subsidiaries in Israel and Delaware. Chemomab is headquartered in Tel Aviv-Yafo, Tel Aviv, Israel.
For a complete picture of CM-101’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
